FLAXEDIL
Pre-Launchgallamine triethiodide
NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLAXEDIL (gallamine triethiodide) is an injectable neuromuscular blocking agent used as a muscle relaxant during anesthesia and surgery. The mechanism of action involves competitive antagonism at the nicotinic acetylcholine receptor at the neuromuscular junction. It is administered intravenously to facilitate intubation and maintain muscle relaxation during surgical procedures.
Pre-Launch
Pre-launch stage suggests minimal current commercial infrastructure; career opportunities tied to launch planning and establishment of field presence upon approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FLAXEDIL is in pre-launch stage with no linked job openings currently, indicating early-stage portfolio presence. Career opportunities will materialize around regulatory approval and commercial launch, particularly in roles supporting market entry and physician adoption in anesthesia/surgical settings.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.